Joanne M. Jeter, M.D.

Joanne M. Jeter, M.D.
Medical Oncologist
Clinical Expertise
  • Clinical Cancer Genomics
Academic Appointments
  • Clinical Professor, Department of Medical Oncology & Therapeutics Research
Clinical Teams
Clinical Cancer Genomics
Medical Oncology & Therapeutics Research
Research Teams
Medical Oncology & Therapeutics Research

Recognizing that each patient has a unique story, Joanne Jeter, M.D., strives to have a positive impact on that story as an expert in clinical cancer genomics. She relishes the chance to help patients manage their genetic risk, educating them about their options so they can make more informed decisions and influencing how their family members approach their own cancer risk.

Named a fellow of the American Society of Clinical Oncology (ASCO) shortly before joining City of Hope® in 2023, Dr. Jeter is a seasoned clinical researcher with a many peer-reviewed scientific publications to her name. Her investigations have been funded by the National Cancer Institute, SWOG (formerly the Southwest Oncology Group) and ASCO. Dr. Jeter has given invited lectures internationally on oncology, end-of-life care and cancer genetics. Before joining City of Hope, she held faculty appointments at the University of Utah, Ohio State University and the University of Arizona.

She was drawn to City of Hope for its reputation for groundbreaking cancer care. "As I saw more and more of my respected colleagues gravitate to the program at City of Hope and heard about the leading-edge work they strive to do,” she says, “I knew I wanted to be a part of it.”

Location

Education & Experience

Board Certifications
  • 2012, American Board of Internal Medicine (Internal Medicine)
  • 2005, American Board of Internal Medicine (Medical Oncology)
Degrees

  • 2005, Master of Science, Clinical Trials Design and Statistical Analysis, University of Michigan, Ann Arbor, Michigan

  • 1999, Doctor of Medicine, University of Texas Health Sciences Center at Houston, Texas

Fellowship
  • 2005, University of Michigan Medical School Ann Arbor, Michigan
Residency
  • 2002, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama
Internship
  • 2000, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama
Professional Experience
  • 2023-present, Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California
  • 2023, Professor, Division of Medical Oncology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah
  • 2015-2020, Attending Physician, The Ohio State University, Wexner Medical Center, Columbus, Ohio
  • 2015-2020, Associate Professor of Medicine, Sections, Human Genetics and Medical Oncology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
  • 2014-2015, Associate Professor of Medicine, Section, Hematology/Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona

Awards & Memberships

Awards

  • 2016-present, Castle Connelly Top Doctor
  • 2015, Attending of the Year, Division of Hematology-Oncology, University of Arizona, Tucson, Arizona
  • 2014, Early Career Reviewer, National Institutes of Health
  • 2012, Outstanding Abstract Award, Paris Melanoma Conference
  • 2011, US News and World Report Top Doctor
  • 2010, National Institutes of Health Merit Award (group award for PDQ Genetics Group)
  • 2010, Coltman Fellowship Award, Southwest Oncology Group Hope Foundation
  • 2006, Career Development Award, American Society of Clinical Oncology

Memberships

  • 2021-present, Member, Research Committee, Cancer Group of the Americas
  • 2021-present, Track Leader, Prevention, Risk Reduction, Hereditary Cancer Genetics, American Society of Clinical Oncology, Scientific Program Committee
  • 2021-present, Member & Consultant, American Society of Clinical Oncology, Education Committee
  • 2021-present, Invited M.D. Representative, American Cancer Society, Multidisciplinary Expert Group, Melanoma/Sarcoma Disease Team, Quality Integration Committee, Commission on Cancer
  • 2020-present, Committee Member, American Society of Clinical Oncology, Scientific Program Committee
  • 2018-2019, Track Leader, American Society of Clinical Oncology, Cancer Prevention, Epidemiology, and Hereditary Genetics
  • 2017-present, Invited Mentor, American Society of Clinical Oncology, Women’s Networking Lounge, ASCO Annual Meeting
  • 2016-2019, Member, American Society of Clinical Oncology, Cancer Education Committee
  • 2014-present, Member, NRG Oncology, Cancer Prevention Committee
  • 2013-2016, Member, American Society of Clinical Oncology, Cancer Prevention Committee
  • 2012-present, Member, Southwest Oncology Group, Melanoma Prevention Working Group Planning Committee
  • 2009-2011, Member, American Society of Clinical Oncology, Clinical Practices Committee
  • 2008-2010, Member, American Society of Clinical Oncology, Cancer Education Committee
  • 2007-present, Member, Southwest Oncology Group, Melanoma and Cancer Prevention and Control Research Committees
  • 2004-2005, Member, National Comprehensive Cancer Network, Genetics/Familial High-Risk Assessment: Breast and Ovarian Cancer Panel

Publications

  • Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G, Melanoma Research Foundation. (2021). The state of melanoma: Emergent challenges and opportunities. Clin Cancer Res, 27(10), 2678-2697.
  • Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM (2020). Prognostic gene expression profiling in cutaneous melanoma: Identifying the knowledge gaps and assessing the clinical benefit. JAMA Dermatol, 156(9), 1004-1011.
  • Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, Philip S, Phillips C, Shane K, Martin A, Weinstein V, Pilarski R, Jeter J, Sweet K, Hatten B, Wurtmann EJ, Phippen S, Bro D, Schwartz MD (2020). Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. Transl Behav Med, 10(2), 337-346.
  • Boru G, Grosel TW, Pilarski R, Stautberg M, Massengill JB, Jeter J, Singh A, Marino MJ, McElroy JP, Davidorf FH, Cebulla CM, Abdel-Rahman MH (2019). Germline large deletion of BAP1 and decreased expression in non-tumor choroid in uveal melanoma patients with high risk for inherited cancer. Genes Chromosomes Cancer, 58(9), 650-656.
  • Garcia A, Frahm C, Jeter JM, Abraham I, Chambers SK, Cragun JM, McBride A (2019). Incidence of hypersensitivity reactions to carboplatin or paclitaxel in patients with ovarian, fallopian tube, or primary peritoneal cancer with or without BRCA1 or BRCA2 Mutations. J Adv Pract Oncol, 10(5), 428-439.
  • Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, Jeter J, Martin JR, Babiker HM, McBride A, Abraham I (2019). The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate, 79(8), 880-895.
  • Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL Jr, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Jeter, Page 11 Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB (2019). Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer, 125(1), 18-44.
  • Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I (2018). BRCA1 and BRCA2 gene mutations and colorectal cancer risk: Systematic review and meta-analysis. J Natl Cancer Inst, 110(11), 1178-1189.
  • Cuellar LE, Anampa-Guzmán A, Holguín AM, Velarde J, Portillo-Alvarez D, Zuñiga-Ninaquispe MA, Luna-Reyes ER, Vásquez J, Jeter JM, Winkfield KM (2018). Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: A Peruvian experience. Infect Agent Cancer, 13, 27.
  • Pulluri B, Kumar A, Shaheen M, Jeter J, Sundararajan S (2017). Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. Pharmacol Res, 123, 95-102.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.